JP2018134084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018134084A5 JP2018134084A5 JP2018071318A JP2018071318A JP2018134084A5 JP 2018134084 A5 JP2018134084 A5 JP 2018134084A5 JP 2018071318 A JP2018071318 A JP 2018071318A JP 2018071318 A JP2018071318 A JP 2018071318A JP 2018134084 A5 JP2018134084 A5 JP 2018134084A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- injury
- isolated polypeptide
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000014674 injury Diseases 0.000 claims 47
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 230000006378 damage Effects 0.000 claims 24
- 230000008736 traumatic injury Effects 0.000 claims 22
- 208000027418 Wounds and injury Diseases 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000001647 Renal Insufficiency Diseases 0.000 claims 14
- 201000006370 kidney failure Diseases 0.000 claims 14
- 210000004556 brain Anatomy 0.000 claims 10
- 206010021143 Hypoxia Diseases 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010003497 Asphyxia Diseases 0.000 claims 6
- 208000027534 Emotional disease Diseases 0.000 claims 6
- 208000010412 Glaucoma Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 206010015037 epilepsy Diseases 0.000 claims 6
- 208000028867 ischemia Diseases 0.000 claims 6
- 210000001428 peripheral nervous system Anatomy 0.000 claims 6
- 210000000278 spinal cord Anatomy 0.000 claims 6
- 230000008733 trauma Effects 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 230000007954 hypoxia Effects 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000010496 Heart Arrest Diseases 0.000 claims 4
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 201000009906 Meningitis Diseases 0.000 claims 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 4
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 206010014599 encephalitis Diseases 0.000 claims 4
- 230000004968 inflammatory condition Effects 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 210000001525 retina Anatomy 0.000 claims 4
- 208000009174 transverse myelitis Diseases 0.000 claims 4
- 208000028389 Nerve injury Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000008764 nerve damage Effects 0.000 claims 3
- 230000002669 organ and tissue protective effect Effects 0.000 claims 3
- 230000000472 traumatic effect Effects 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000001408 Carbon monoxide poisoning Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010010254 Concussion Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 2
- 201000006306 Cor pulmonale Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010013647 Drowning Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000022555 Genital disease Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000009773 Insulin Coma Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 2
- 206010051606 Necrotising colitis Diseases 0.000 claims 2
- 206010028885 Necrotising fasciitis Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010031252 Osteomyelitis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims 2
- 208000008601 Polycythemia Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010040576 Shock hypoglycaemic Diseases 0.000 claims 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 2
- 208000010513 Stupor Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 208000012931 Urologic disease Diseases 0.000 claims 2
- 206010053648 Vascular occlusion Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 claims 2
- 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 230000009514 concussion Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 208000002296 eclampsia Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 230000006371 metabolic abnormality Effects 0.000 claims 2
- 210000002161 motor neuron Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 2
- 201000007970 necrotizing fasciitis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 210000001328 optic nerve Anatomy 0.000 claims 2
- 208000024691 pancreas disease Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 230000000506 psychotropic effect Effects 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000032253 retinal ischemia Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000033764 rhythmic process Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 210000003497 sciatic nerve Anatomy 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- 208000014001 urinary system disease Diseases 0.000 claims 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000007971 neurological deficit Effects 0.000 claims 1
- 230000004693 neuron damage Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70574105P | 2005-08-05 | 2005-08-05 | |
| US60/705,741 | 2005-08-05 | ||
| US70627605P | 2005-08-08 | 2005-08-08 | |
| US60/706,276 | 2005-08-08 | ||
| US83173706P | 2006-07-18 | 2006-07-18 | |
| US60/831,737 | 2006-07-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016114010A Division JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013151A Division JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018134084A JP2018134084A (ja) | 2018-08-30 |
| JP2018134084A5 true JP2018134084A5 (enExample) | 2018-11-08 |
Family
ID=37728020
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525285A Expired - Fee Related JP5274253B2 (ja) | 2005-08-05 | 2006-08-07 | 組織保護ペプチド及びその使用 |
| JP2013027479A Expired - Fee Related JP5918155B2 (ja) | 2005-08-05 | 2013-02-15 | 組織保護ペプチド及びその使用 |
| JP2015020020A Expired - Fee Related JP6158235B2 (ja) | 2005-08-05 | 2015-02-04 | 組織保護ペプチド及びその使用 |
| JP2016114010A Expired - Fee Related JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
| JP2018071318A Pending JP2018134084A (ja) | 2005-08-05 | 2018-04-03 | 組織保護ペプチド及びその使用 |
| JP2020013151A Pending JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525285A Expired - Fee Related JP5274253B2 (ja) | 2005-08-05 | 2006-08-07 | 組織保護ペプチド及びその使用 |
| JP2013027479A Expired - Fee Related JP5918155B2 (ja) | 2005-08-05 | 2013-02-15 | 組織保護ペプチド及びその使用 |
| JP2015020020A Expired - Fee Related JP6158235B2 (ja) | 2005-08-05 | 2015-02-04 | 組織保護ペプチド及びその使用 |
| JP2016114010A Expired - Fee Related JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013151A Pending JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8071554B2 (enExample) |
| EP (5) | EP1924276A4 (enExample) |
| JP (6) | JP5274253B2 (enExample) |
| KR (7) | KR101713368B1 (enExample) |
| CN (2) | CN103724418B (enExample) |
| AU (1) | AU2006278264B2 (enExample) |
| BR (1) | BRPI0614529A8 (enExample) |
| CA (3) | CA2618396C (enExample) |
| DK (3) | DK2371855T3 (enExample) |
| EA (1) | EA015672B1 (enExample) |
| ES (3) | ES2653790T3 (enExample) |
| HU (3) | HUE035793T2 (enExample) |
| IL (3) | IL189287A (enExample) |
| IN (1) | IN2014CN02050A (enExample) |
| LT (2) | LT2594279T (enExample) |
| MX (3) | MX2008001509A (enExample) |
| NO (1) | NO20081112L (enExample) |
| NZ (1) | NZ565937A (enExample) |
| PL (3) | PL2540309T3 (enExample) |
| PT (3) | PT2540309T (enExample) |
| SG (2) | SG10201805825SA (enExample) |
| SI (3) | SI2371855T1 (enExample) |
| UA (1) | UA100222C2 (enExample) |
| WO (1) | WO2007019545A2 (enExample) |
| ZA (1) | ZA201101890B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| US9585932B2 (en) * | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
| US8653028B2 (en) * | 2005-04-29 | 2014-02-18 | Rui Rong Yuan | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| SI2371855T1 (sl) | 2005-08-05 | 2015-11-30 | Araim Pharmaceuticals, Inc. | Peptidi, ki ščitijo tkiva, in načini njihove uporabe |
| WO2007142288A1 (ja) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | エリスロポエチンを用いた虚血性疾患の治療 |
| EP2081956B1 (en) | 2006-11-13 | 2013-03-20 | Charité - Universitätsmedizin Berlin | Method of cell culture and method of treatment comprising a vepo protein variant |
| NZ621196A (en) * | 2008-01-22 | 2015-08-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| AU2016203452B2 (en) * | 2008-01-22 | 2018-02-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| AU2014203195B2 (en) * | 2008-01-22 | 2016-03-31 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| WO2012051581A2 (en) * | 2010-10-14 | 2012-04-19 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| US9566349B2 (en) * | 2010-10-14 | 2017-02-14 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| CN102180948A (zh) * | 2011-03-03 | 2011-09-14 | 复旦大学附属中山医院 | 一种具有肾脏保护作用的短肽及其制备方法和应用 |
| CN102212111B (zh) * | 2011-05-05 | 2014-04-30 | 中国人民解放军第三军医大学 | 小分子多肽和小分子多肽脂质体及其运用 |
| EP2736530B1 (en) * | 2011-07-27 | 2018-06-06 | Neumedicines, Inc | Use of il-12 to generate endogenous erythropoietin |
| WO2013042118A1 (en) * | 2011-09-20 | 2013-03-28 | A.A. Cash Technology Ltd | Methods and devices for occluding blood flow to an organ |
| KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
| WO2013158871A1 (en) * | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| KR20160052537A (ko) * | 2013-07-17 | 2016-05-12 | 아라임 파마슈티칼즈, 인크. | 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| CN104744593A (zh) * | 2013-12-25 | 2015-07-01 | 深圳先进技术研究院 | 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用 |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| CN105968172A (zh) * | 2014-06-22 | 2016-09-28 | 马恒标 | 组织保护活性多肽sl2及其应用 |
| SG11201802777XA (en) * | 2015-10-14 | 2018-05-30 | X Therma Inc | Compositions and methods for reducing ice crystal formation |
| EP3448415A4 (en) | 2016-04-29 | 2019-11-06 | Araim Pharmaceuticals, Inc. | TREATMENT-PROOFING PEPTIDES FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS RELATED TO TISSUE DAMAGE |
| AU2017357374B2 (en) | 2016-11-10 | 2023-05-18 | Asc Regenity Ltd. | Cosmetic formulations for topical applications containing erythropoietin-derived molecules |
| KR101965814B1 (ko) | 2017-02-27 | 2019-08-13 | 재단법인 대구경북과학기술원 | 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용 |
| US11260101B2 (en) | 2017-02-28 | 2022-03-01 | Jinan University | Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof |
| CN108503690B (zh) * | 2017-02-28 | 2020-07-03 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
| JP7481261B2 (ja) * | 2018-04-08 | 2024-05-10 | ブリム バイオテクノロジー インク | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
| KR102300060B1 (ko) | 2018-06-12 | 2021-09-08 | 주식회사 엘지에너지솔루션 | 2열 터미널 구조의 pcb 다이렉트 커넥터 |
| WO2020055768A1 (en) | 2018-09-10 | 2020-03-19 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
| CN112390877B (zh) * | 2019-08-16 | 2022-10-04 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
| CN118255845B (zh) * | 2022-12-27 | 2025-07-11 | 上海瑞吉康生物医药有限公司 | 相分离逆转多肽的变体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US4558006A (en) * | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
| DE3924746A1 (de) | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| AU6501390A (en) | 1989-09-21 | 1991-04-18 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| WO2004031211A2 (en) * | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
| US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| KR100459984B1 (ko) * | 1995-06-07 | 2005-06-20 | 아피맥스 테크놀로지스, 엔.브이. | 에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드 |
| AU4267297A (en) * | 1997-09-11 | 1998-09-22 | Regents Of The University Of California, The | Method of alleviating neuropathic pain |
| US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| TR200103785T2 (tr) | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| AU2001252650A1 (en) * | 2000-04-28 | 2001-11-12 | Effector Cell Institute | Novel derivative of cell chemotactic factor |
| JP4656814B2 (ja) * | 2000-12-20 | 2011-03-23 | エフ．ホフマン−ラ ロシュ アーゲー | エリスロポエチンコンジュゲート |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| MXPA03006990A (es) | 2001-02-06 | 2003-11-18 | Merck Patent Gmbh | Eritropoyetina (epo) modificada con inmunogenicidad reducida. |
| DE60232870D1 (de) * | 2001-04-04 | 2009-08-20 | Genodyssee | Neue polynukleotide und polypeptide des erythropoietingens |
| KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| EA010200B1 (ru) | 2002-07-01 | 2008-06-30 | Дзе Кеннет С. Уоррен Инститьют, Инк. | Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов |
| KR100478455B1 (ko) | 2002-08-19 | 2005-03-22 | 삼성전자주식회사 | 전자렌지 |
| EP1545586A4 (en) | 2002-09-09 | 2007-09-26 | Warren Pharmaceuticals Inc | LONG-ACTING ERYTHROPOIETINES THAT MAINTAIN THE PROTECTIVE ACTIVITY OF THE TISSUE OF ENDOGENEURY ERYTHROPOIETIN |
| JP2004305006A (ja) * | 2003-04-01 | 2004-11-04 | Japan Science & Technology Agency | 人工調製肺サーファクタント |
| DE602004029349D1 (de) * | 2003-04-25 | 2010-11-11 | Univ Pittsburgh | Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und -regeneration |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| BRPI0409650A (pt) | 2003-09-09 | 2006-04-25 | Warren Pharmaceuticals Inc | métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica |
| AU2004277954A1 (en) | 2003-09-29 | 2005-04-14 | The Kenneth S Warren Institute, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| US8653028B2 (en) | 2005-04-29 | 2014-02-18 | Rui Rong Yuan | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| EP2385061A3 (en) | 2005-05-10 | 2012-02-22 | Neoloch Aps | Neuritogenic peptides |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| SI2371855T1 (sl) | 2005-08-05 | 2015-11-30 | Araim Pharmaceuticals, Inc. | Peptidi, ki ščitijo tkiva, in načini njihove uporabe |
| EP2109690B9 (en) | 2007-11-29 | 2012-10-24 | MOLECULAR HEALTH GmbH | Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use. |
| NZ621196A (en) | 2008-01-22 | 2015-08-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| JP2011523353A (ja) * | 2008-04-28 | 2011-08-11 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 細胞透過のための過剰に荷電されたタンパク質 |
| WO2011022056A2 (en) | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
-
2006
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko not_active Expired - Fee Related
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Ceased
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Ceased
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en active Active
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en not_active Ceased
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en active Active
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Ceased
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko not_active Ceased
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko not_active Expired - Fee Related
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Ceased
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en active Active
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
-
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
-
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
-
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018134084A5 (enExample) | ||
| JP2016196480A5 (enExample) | ||
| Lemaitre et al. | The trigeminocardiac reflex: A comparison with the diving reflex in humans | |
| Fulton et al. | Retinal degenerative and hypoxic ischemic disease | |
| AU2010251788B2 (en) | Novel agents for ameliorating motor disorder | |
| Li et al. | Systemic hypothermia induced within 10 hours after birth improved neurological outcome in newborns with hypoxic-ischemic encephalopathy | |
| WO2019029273A1 (zh) | 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用 | |
| WO2019029274A1 (zh) | 4-氧-烷基化特特拉姆酸类化合物及其制备方法 | |
| JP2016508036A5 (enExample) | ||
| Bugrov et al. | Influence of If-current blockade on rat heart contractility with a model of myocardial infarction | |
| US20090163432A1 (en) | Therapeutic Agent for Corneal Diseases | |
| Ermatov et al. | Results of life quality assessment in rehabilitation treatment of children with traumatic brain injury | |
| Jolly | Treatment of traumatic brain injury in Morepork owls: a review of diagnostic and treatment options | |
| Fotbolcu et al. | Reversible myocardial stunning due to carbon monoxide exposure | |
| Kestane | Diabetic Retinopathy and Stem Cell Therapy | |
| Li et al. | The effect of mild hypothermia on Nogo-A and neurological function in the brain after cardiopulmonary resuscitation in rats | |
| Arias-Carrión et al. | Cell transplantation: a future therapy for narcolepsy? | |
| Renziak et al. | Features of daily patterns of blood flow parameters in the internal carotid arteries in primary open-angle glaucoma | |
| Bibhu et al. | Application of cardioplegic solution in clinical practice | |
| Balykova et al. | ROHHAD syndrome: clinical case and literature review | |
| Andrews et al. | The Effects of Stem Cells Plus Lithium on the Recovery of Spinal Cord Injury | |
| Yi-qing et al. | Analysis of genetic and clinical characteristics of Charcot-Marie-Tooth disease patients caused by ARSs gene variation | |
| US20250064802A1 (en) | Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases | |
| Fuller et al. | Proceedings of the 249th Otago Medical School Research Society Meeting-Research Staff Speaker Awards; 24 Jul 2019 | |
| CN117736995A (zh) | 转基因干细胞及其用于治疗失眠症治疗方法 |